NCT04432467 is a Phase 1, PHASE2 clinical trial of Autologous mesenchymal stem cells in Chronic Endometritis, sponsored by Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus.

What drugs are being tested in NCT04432467?

Interventions in NCT04432467: Autologous mesenchymal stem cells, standard treatment.

What condition does NCT04432467 study?

NCT04432467 studies Chronic Endometritis, Uterus; Scar, Uterine Synechiae, Fallopian Tube Obstruction.

Is NCT04432467 still recruiting?

NCT04432467 is currently completed. Last updated 10 December 2021.

Last reviewed 2021-12-10 · How we verify

NCT04432467

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fertility Restoration Using Autologous Mesenchymal Stem Cells

Completed Phase 1, PHASE2 Last updated 10 December 2021

What this trial tests

Phase 1, PHASE2 trial testing Autologous mesenchymal stem cells in Chronic Endometritis in 10 participants. Completed in 30 September 2021.

Timeline

1 October 2020

Primary endpoint
30 September 2021

30 September 2021

Quick facts

Lead sponsor	Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 October 2020
Primary completion	30 September 2021
Estimated completion	30 September 2021
Sites	1 location across Belarus

Drugs / interventions tested

Autologous mesenchymal stem cells — full drug profile →
standard treatment

Conditions studied

Chronic Endometritis — all drugs for Chronic Endometritis →
Uterus; Scar — all drugs for Uterus; Scar →
Uterine Synechiae — all drugs for Uterine Synechiae →
Fallopian Tube Obstruction — all drugs for Fallopian Tube Obstruction →

Sponsor

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Who can join

Adults 18 to 45, female only, with Chronic Endometritis or Uterus; Scar. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment of the patients with scarring and adhesions in the uterus resulting from caesarean section or chronic inflammation in the mucosa of the uterus and fallopian tubes and preventing the occurrence of these effects in the future

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Endometrial Stem Cells and Their Applications in Intrauterine Adhesion.
Chen K, Zheng S, Fang F. · · 2023 · cited 11× · PMID 36891869 · DOI 10.1177/09636897231159561
Stem cell treatments for female reproductive disorders: a comprehensive review.
Nair R, Agarwal P, Gadre MA, Vasanthan KS, et al · · 2025 · cited 2× · PMID 40708035 · DOI 10.1186/s13048-025-01750-y

Verify or expand the search:

Other trials of Autologous mesenchymal stem cells

Trials testing the same drug.

NCT04146519 — Parkinson's Disease Therapy Using Cell Technology · Phase 2, PHASE3 · unknown
NCT03333681 — Evaluation of Stem Cell Therapy Effects on the Immune Response in Rheumatoid Arthritis Patients · Phase 1 · completed

Other recruiting trials for Chronic Endometritis

Currently open trials in the same condition.

NCT07180563 — Randomized Controlled Trial of Berberine in Combination With Doxycycline in the Treatment of Chronic Endometritis · Phase 1, PHASE2 · recruiting
NCT07488949 — Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF) · NA · recruiting

Other Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus trials

Trials by the same sponsor.

NCT06167564 — Allergy Diagnostic Test Based on Microchip Technology · NA · unknown
NCT05654766 — Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies · unknown
NCT05520125 — Treatment of Patients With Bone Tissue Defects Using Mesenchymal Stem Cells Enriched by Extracellular Vesicles · Phase 1, PHASE2 · unknown
NCT05520112 — Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells · Phase 1, PHASE2 · unknown
NCT05214014 — Treatment of Systemic Sclerosis With Autologous Regulatory Т-cells · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04432467 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Last refreshed: 10 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04432467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing